Could Florida’s Medical Marijuana Residency Requirement Violate the Commerce Clause?

TL;DR

A new Congressional Research Service report highlights a growing disagreement among federal courts over whether state marijuana laws that favor residents violate the Constitution’s Dormant Commerce Clause. Two federal appeals courts have applied the Commerce Clause to marijuana markets, while the Ninth Circuit has taken the opposite view, largely because marijuana commerce has been prohibited under federal law.

A major development may complicate that argument. In April 2026, the U.S. Department of Justice placed certain marijuana products subject to qualifying state medical marijuana licenses in Schedule III of the federal Controlled Substances Act. That does not make all marijuana activity federally legal, and it does not settle the constitutional issue. It does, however, potentially weaken the argument that state-regulated medical marijuana should simply be treated as illegal commerce receiving no protection under the Commerce Clause.

No court has ruled that Florida’s medical marijuana patient residency requirement is unconstitutional. Still, there is now a credible argument worth examining: If a nonresident patient is physically in Florida, has a qualifying condition, sees a qualified Florida physician, registers with the state, purchases only from a Florida-licensed Medical Marijuana Treatment Center, and follows all Florida rules, what legitimate regulatory purpose is served by excluding that patient solely because the patient lives in another state?

A New Congressional Report Raises the Question

On September 3, 2026, the Congressional Research Service, or CRS, published a Legal Sidebar titled State Marijuana Laws and the Dormant Commerce Clause. CRS is the nonpartisan research arm that provides legal and policy analysis to Congress.

The report does not specifically address Florida’s medical marijuana patient residency requirement. Instead, it examines federal court cases challenging state marijuana laws that favor residents over nonresidents. Those cases raise a broader constitutional question that could have direct implications for Florida.

The answer is far from settled. Federal courts disagree about whether the Dormant Commerce Clause applies to state marijuana markets, and the U.S. Supreme Court has not resolved the issue.

What Is the Dormant Commerce Clause?

The Commerce Clause of the U.S. Constitution gives Congress the power to regulate commerce among the states. The Supreme Court has also interpreted the Commerce Clause as limiting certain actions by the states themselves. This principle is commonly known as the Dormant Commerce Clause.

The basic idea is straightforward. States generally cannot create protectionist economic rules that unfairly favor their own residents or businesses over people or businesses from other states.

That leads to an interesting question: What happens when a state creates a legal medical marijuana market but limits participation in that market based on where someone lives?

That question matters in Florida.

Florida Requires Patients to Establish Residency

Florida generally requires a medical marijuana patient to be either a Florida resident or a qualifying seasonal resident.

Consider two patients. Both have the same qualifying medical condition. Both are physically present in Florida. Both are examined by the same qualified Florida physician, who determines that medical marijuana is appropriate for each patient.

One patient lives in Tampa. The other lives in Atlanta and is visiting Florida.

The Tampa resident can qualify for Florida’s Medical Marijuana Use Registry. The Atlanta resident generally cannot unless that patient also meets Florida’s requirements for seasonal residency.

The medical difference between the patients? There isn’t one.

The difference is where they live.

Florida’s 31-Day Rule Shows How Unusual the Distinction Can Be

Florida’s treatment of seasonal residents makes the issue even more interesting.

Under Florida law, a seasonal resident must temporarily reside in Florida for at least 31 consecutive days, maintain a temporary residence in Florida, return to another state or jurisdiction at least once during the year, and meet Florida’s other residency requirements.

Consider two patients.

Patient A rents a Florida condominium for 31 consecutive days. The patient has a qualifying condition, establishes the required temporary Florida residence, provides the necessary documentation, and otherwise satisfies Florida’s requirements. That patient may qualify as a seasonal resident.

Patient B spends the same 31 days in Florida but stays in a hotel rather than establishing a temporary Florida residence. Patient B has the same medical condition, sees the same Florida physician, and is physically present in Florida for exactly the same amount of time. Yet Patient B may not satisfy Florida’s seasonal-residency requirement.

Or change the facts slightly. Suppose Patient B rents the same condominium, but for only 30 days.

Same patient. Same physician. Same diagnosis. Same medical need. Different result.

That raises an obvious medical question: What does renting a Florida residence for 31 days tell us about whether medical marijuana is medically appropriate for that patient?

Very little.

The constitutional question may be more important: Why is that distinction necessary for Florida to safely regulate the patient and the medical marijuana the patient purchases?

The Maine Case: Northeast Patients Group

The First Circuit addressed a related residency issue in Northeast Patients Group v. United Cannabis Patients & Caregivers of Maine in 2022.

Maine required officers and directors of medical marijuana dispensaries to be Maine residents. The First Circuit held that the requirement violated the Dormant Commerce Clause.

Maine raised an obvious defense. Marijuana was prohibited under federal law, so why should the Constitution protect interstate commerce involving something Congress had prohibited?

The First Circuit rejected that argument. It concluded that an interstate medical marijuana market existed despite federal prohibition.

One part of the decision is particularly interesting when thinking about patients. The court noted that Maine itself encouraged people from outside the state to participate in its medical marijuana market as customers.

The case involved marijuana businesses, not a patient’s right to participate in a state medical marijuana program. That is an important distinction. Still, the reasoning raises a question for Florida: If the Dormant Commerce Clause can prevent a state from excluding nonresident marijuana business owners, could it also prevent a state from excluding otherwise qualified nonresident medical marijuana patients?

No federal appellate court has answered that specific question.

The Second Circuit Also Applied the Commerce Clause

The Second Circuit reached a similar conclusion in Variscite NY Four, LLC v. New York State Cannabis Control Board.

New York had given certain marijuana license applicants an advantage based on marijuana convictions under New York law. The Second Circuit concluded that the challengers were likely to succeed on their Dormant Commerce Clause claim.

The court rejected the idea that Congress’s prohibition of marijuana automatically gives individual states permission to discriminate against people from other states.

The distinction is important. Congress may restrict or prohibit interstate marijuana commerce. That does not necessarily mean Congress has authorized Florida, New York, Maine, or another state to favor its own residents.

The Ninth Circuit Disagrees

There is a significant weakness in this constitutional argument.

In 2026, the Ninth Circuit decided Peridot Tree WA, Inc. v. Washington State Liquor & Cannabis Control Board and took the opposite approach.

The Ninth Circuit concluded that the Dormant Commerce Clause does not protect interstate marijuana commerce when Congress has prohibited that commerce under federal law. Put simply, the court questioned why judges should use the Commerce Clause to protect a national commercial market that Congress itself had prohibited.

That creates a real disagreement among the federal courts. The First and Second Circuits have applied the Dormant Commerce Clause to state marijuana markets. The Ninth Circuit has refused to do so.

Florida is in the Eleventh Circuit, which has not decided this specific issue. Therefore, it would be too strong to say that Florida’s patient residency requirement clearly violates the Constitution.

Does Schedule III Change the Analysis?

There has been an important federal development since the Ninth Circuit decided Peridot Tree.

In April 2026, the U.S. Department of Justice placed marijuana products subject to qualifying state medical marijuana licenses in Schedule III of the Controlled Substances Act.

This does not mean that all marijuana is now federally legal. It also does not answer the Dormant Commerce Clause question or erase the Ninth Circuit’s decision.

It may, however, weaken an important part of the reasoning behind that decision.

The Ninth Circuit’s argument depends heavily on the idea that courts should not use the Dormant Commerce Clause to protect commerce in a product that the federal government prohibits. But the federal government’s treatment of state-regulated medical marijuana has now changed in an important way.

The federal government is no longer dealing with the entire state-regulated medical marijuana market simply as commerce in a Schedule I substance. DOJ’s Schedule III action expressly recognizes marijuana products connected to qualifying state medical marijuana programs.

That creates a new question:

If the federal government itself recognizes certain state-regulated medical marijuana within Schedule III, is it still correct to treat the entire state medical marijuana market as illegal commerce that receives no protection from discriminatory state laws?

The courts have not answered that question.

Schedule III therefore does not prove that the First and Second Circuits are correct or that the Ninth Circuit is wrong. But it adds another reason why the constitutional issue is unsettled and why the Ninth Circuit’s federal-illegality rationale may become harder to apply to state medical marijuana programs.

Florida Has Legitimate Interests

Florida unquestionably has legitimate reasons to regulate medical marijuana closely.

The state has an interest in preventing diversion, protecting public safety, supervising physicians, tracking purchases, enforcing possession limits, regulating products, and ensuring that marijuana is obtained only through licensed Medical Marijuana Treatment Centers.

The question is not whether Florida can regulate medical marijuana. It can.

The constitutional question is narrower: Does Florida need to discriminate based on residency to accomplish those legitimate goals?

That may be much harder to establish.

Florida Could Regulate Nonresident Patients Without Giving Up Control

Removing the residency requirement would not require Florida to create an unregulated marijuana tourism market.

A nonresident patient could still be required to:

• Be physically present in Florida.
• Have a condition that qualifies under Florida law.
• Be examined and certified by a qualified Florida physician.
• Register with Florida’s Medical Marijuana Use Registry.
• Purchase only from Florida-licensed Medical Marijuana Treatment Centers.
• Follow Florida’s purchasing and possession limits.
• Comply with all other Florida medical marijuana requirements.

In other words, Florida could allow qualified nonresidents into the same regulated system it already uses rather than creating a separate system for visitors.

Nothing would need to cross state lines. The physician would be licensed in Florida. The patient would be physically present in Florida. The medical marijuana would be purchased from a Florida-licensed MMTC and regulated under Florida law.

The primary difference would be the patient’s permanent home address.

That leads directly to the constitutional question: If Florida can accomplish its public-safety and regulatory goals without discriminating based on residency, why should residency determine whether a medically qualified patient can participate?

Residency Is Not a Medical Diagnosis

There is also a basic healthcare issue.

Residency tells a physician almost nothing about whether medical marijuana is appropriate for a particular patient. A Florida resident and a Georgia resident can have the same diagnosis, symptoms, medical history, and treatment needs.

Cancer does not change when someone crosses the Georgia-Florida border. Neither does PTSD, multiple sclerosis, Parkinson’s disease, chronic pain, or another qualifying condition.

If a qualified Florida physician examines a patient who is physically present in Florida, determines that the patient has a qualifying condition, and concludes that medical marijuana is appropriate, why should the patient’s ZIP Code override that medical judgment?

That has always been a policy question.

The recent CRS report, the growing split among federal appeals courts, and the federal government’s changing treatment of state-regulated medical marijuana suggest that it may also be a constitutional question.

What Is the Weakest Part of the Commerce Clause Argument?

Any fair analysis should acknowledge that there are meaningful weaknesses.

First, marijuana remains a federally controlled substance. Schedule III does not mean that every activity permitted under a state medical marijuana program is automatically lawful under federal law.

Second, the existing federal appellate cases primarily concern marijuana businesses, licenses, or ownership. They do not establish a constitutional right for a nonresident patient to participate in another state’s medical marijuana program.

Third, Florida can argue that its patient residency requirement is not traditional economic protectionism. Florida is not protecting Florida dispensaries from out-of-state dispensaries. In fact, allowing nonresident patients would presumably create more customers for Florida MMTCs.

Florida could characterize the residency requirement as simply defining who is eligible to participate in a state medical program involving a federally controlled substance.

Those are legitimate arguments, and a court could accept them.

So Is Florida’s Medical Marijuana Residency Requirement Unconstitutional?

We don’t know yet.

No federal court has held that Florida’s medical marijuana patient residency requirement violates the Dormant Commerce Clause.

The First and Second Circuits provide meaningful support for such an argument. The Ninth Circuit provides meaningful authority against it. The Eleventh Circuit has not resolved the question.

The federal landscape is also changing. The federal government’s April 2026 Schedule III action involving qualifying state medical marijuana programs potentially weakens the simple argument that state medical marijuana markets should receive no Commerce Clause protection because marijuana commerce is entirely illegal under federal law.

And Florida’s own seasonal-resident rule makes the issue particularly difficult to explain.

A medically qualified patient who establishes a Florida residence for 31 consecutive days may qualify. A patient with the same medical condition who stays in a hotel for those same 31 days may not. A patient who rents the same residence for only 30 days may not.

The diagnosis has not changed. The physician’s medical judgment has not changed. Florida’s ability to regulate the purchase has not changed.

The residency has.

That leaves Florida with a question that may eventually require an answer:

If a patient is physically present in Florida, has a qualifying medical condition, is examined and certified by a qualified Florida physician, registers with the State, purchases only from a Florida-licensed Medical Marijuana Treatment Center, and follows all of Florida’s medical marijuana laws, should Florida be able to deny that patient access solely because the patient lives somewhere else?

The Congressional Research Service did not answer that question.

Neither has the Supreme Court.

But after the federal appellate decisions identified in CRS’s September 2026 report, and the federal government’s changing treatment of state-regulated medical marijuana, it is becoming a harder question to ignore.

DocMJ Helps You Secure Legal Access to Medical Cannabis

We connect Florida residents with state-registered physicians, guide you through the medical marijuana certification process, and help you obtain the registry card that protects you under Florida law. Contact us and carry your cannabis with legal confidence.

Legal Sources

Congressional Research Service, State Marijuana Laws and the Dormant Commerce Clause, Legal Sidebar LSB11475 (Sept. 3, 2026).

Northeast Patients Group v. United Cannabis Patients & Caregivers of Maine, U.S. Court of Appeals for the First Circuit (2022).

Variscite NY Four, LLC v. New York State Cannabis Control Board, U.S. Court of Appeals for the Second Circuit.

Peridot Tree WA, Inc. v. Washington State Liquor & Cannabis Control Board, U.S. Court of Appeals for the Ninth Circuit (2026).

Florida Statutes § 381.986.

U.S. Department of Justice, April 2026 action concerning Schedule III treatment of marijuana products subject to qualifying state medical marijuana licenses.